Peptides / Weight and metabolic

Synthetic analog · 4 amino acids · 575.6 Da

Pancragen (KEDW)

Pancragen is a short synthetic peptide (Lys-Glu-Asp-Trp) from the Khavinson bioregulator family, and no approval as a drug was found. Its studies are in animals and lab cells, with a few small studies in people, mostly on blood sugar. PepBank shows 6 results on Pancragen from 2 studies in people, and 29 from animal and lab studies. The strongest evidence is a trial in people without random groups. Data as of 2026-10-30.

Also known as KEDW, Lys-Glu-Asp-Trp, Pancragen, Pancragen peptide, Pankragen

4 amino acids, from first to lastKEDW

Evidence level: Mostly animal studies29 of 35 results come from studies in animals and lab cells. 2 studies in people.

Results in people

17% of 35 results

Results in animals

34% of 35 results

Results in lab cells

49% of 35 results

From computer models

0% of 35 results

Overview

Pancragen (KEDW) at a glance

What it is	Synthetic analog, 4 amino acids
Approval	Regulatory status not recorded
In sport	Status unknown
Studies	10 studies with results. 8 of them gave Pancragen, with 35 results. 6 in people12 in animals17 in lab cells
Best study in people	Non-randomized trial with 12 people (2013)
Clinical trials	None registered
Community use	Community interest in pancreatic and glucose regulation research

The science

What is Pancragen?

Synthetic Lys-Glu-Asp-Trp amide from the Khavinson bioregulator family.

Amino acids in one chain

Pancragen (KEDW) structure and chemistry

The key facts about the molecule. Long codes are in the closed section below.

Sequence, 4 amino acidsFrom the first amino acid to the last

+K1−E−DW

Darker means more water-repelling+ and − show charge in the bodyOutlined: changed amino acid

Structure

Pancragen (KEDW) is a synthetic analog of 4 amino acids, with no ring, 1 changed amino acid.

Formula

C₂₆H₃₇N₇O₈

Molecular weight

575.6 g/mol

Development

Highest phase: no known clinical development.

Identifiers

PubChem 68451868

Full sequence, SMILES and InChIKey

Three-letter sequence
H-Lys-Glu-Asp-Trp-NH2

InChIKey
WKJHPWJUFPYRSF-LEAZDLGRSA-N

SMILES
C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)N

See charge, composition and 3D structure on the Scientific page

The evidence

What Pancragen studies show

Results grouped by what the studies measured. Each card shows where its results come from.

Mostly animal studies29 of 35 results come from studies in animals and lab cells. 2 studies in people.

Blood sugar

15 results · 5 in people · 10 animal

In 50 percent of older patients with impaired glucose tolerance, pankragen forte significantly reduced plasma glucose during glucose testing. Advances in gerontology = Uspekhi gerontologii, 2013

Heart and blood vessels

1 result · 1 in people

In older patients with impaired glucose tolerance, pankragen forte treatment was consistent with better blood lipids, blood vessel function and less platelet clumping. Advances in gerontology = Uspekhi gerontologii, 2013

All 2 studies in people

In people

In 50 percent of older patients with impaired glucose tolerance, pankragen forte significantly reduced plasma glucose during glucose testing.

2013Advances in gerontology = Uspekhi gerontologii12 people

In people

In older diabetes patients, pancragen lowered fasting glucose, while untreated patients showed no changes.

2011Bulletin of experimental biology and medicine

All 10 Pancragen studies by area Open the Scientific page

Key Pancragen studies

Studies in people come first, then studies in animals and in the lab.

People
[The tetrapeptide pankragen forte efficiency in elderly people with prediabetic state]
Korkushko et al. 2013 · Advances in gerontology = Uspekhi gerontologii · 12 people · cited by 0
2 results
People
Prospects of using pancragen for correction of metabolic disorders in elderly people
Korkushko et al. 2011 · Bulletin of experimental biology and medicine · cited by 4
4 results
Animals
[Correction of impaired glucose tolerance using tetrapeptide (Pancragen) in old female rhesus monkeys]
Goncharova et al. 2015 · Advances in gerontology = Uspekhi gerontologii · 9 subjects · cited by 0
5 results
Animals
Effect of pancragen on blood glucose level, capillary permeability and adhesion in rats with experimental diabetes mellitus
Khavinson et al. 2007 · Bulletin of experimental biology and medicine · cited by 3
3 results
Animals
[Impact of tetrapeptide pancragen on endocrine function of the pancreas in old monkeys]
Goncharova et al. 2014 · Advances in gerontology = Uspekhi gerontologii · cited by 0
4 results

All 10 Pancragen (KEDW) studies

Pancragen clinical trials

ClinicalTrials.gov lists no trial of Pancragen. A trial under another name may exist.

Status and safety

Is Pancragen approved?

FDA

United States

Status unknown

Status unknown.

EMA

European Union

Status unknown

Status unknown.

WADA

Sport

Not recorded

Status unknown.

Regulatory status not recorded. Status unknown.

Laws and labels change, so check the regulator for the current status.

Pancragen side effects and safety

PepBank has no safety result from studies of Pancragen yet. That does not mean Pancragen is safe.

Doses studied (3 shown)

The doses that these studies used. They are not recommendations.

Dose as reported	Class	Species	Route	Duration	Design	Source
500 mkg 2 times a day (morning and evening)	Human	human	Not reported	4 weeks	Trial in people without random groups · n = 12	Korkushko 2013
0,05 mg/animal per day	Animal	Macaca mulatta	intramuscularly	10 days	Study in live animals · n = 9	Goncharova 2015
50 μg/animal per day	Animal	rhesus monkey	intramuscularly	10 days	Study in live animals	Goncharova 2014

From the community

How people use it

What people report online. It comes from forums and guides, not from studies.

Community-reported. Not tested in trials.

The guide describes pancreatic and glucose regulation research. It reports a use pattern, without proof of safety or benefit.

Reported routines and cautions

What people use it for

Community interest in pancreatic and glucose regulation researchS1

Reported regimens

Regimens that community sources report for Pancragen. Community-reported, not tested in trials.
Context	Route	Amount	How often	How long	Agreement	Sources
Community interest in pancreatic and glucose regulation research	subcutaneous injection	1 to 2 mg per dose	once daily	10 to 20 days	Single non-vendor guide. The underlying community reports were not independently verified.	S1

Community sources

S1Pancragen dosage, protocols and mixing | Vial Guide (opens in a new tab)vialguide.com

Gaps

This is one secondary guide. It does not identify the underlying community reports. Other regimens exist in the guide. No official medicine label was established. Product purity and actual use were not independently tested.

Questions and more

Ask a question about Pancragen

The answer links to every study it uses.

What does the evidence say about Pancragen?Is Pancragen tested in people?Compare with Liraglutide Compare with Exenatide (exendin-4)

Sources

Database: PepBank data for Pancragen (data version 308560)
Regulator: FDA status record
Regulator: EMA status record
Regulator: WADA status record
Community: community sources (forums and guides), as summarized in the PepBank community file

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Ask your AI about Pancragen

Curo is a peptide shop. PepBank and Curo have the same owner. See the Curo catalog (opens in a new tab).

Pancragen (KEDW)

Also known as KEDW, Lys-Glu-Asp-Trp, Pancragen, Pancragen peptide, Pankragen

What it is

Synthetic analog, 4 amino acids

Approval

Regulatory status not recorded

In sport

Status unknown

Studies

10 studies with results. 8 of them gave Pancragen, with 35 results.
6 in people12 in animals17 in lab cells

Best study in people

Non-randomized trial with 12 people (2013)

Clinical trials

None registered

Community use

Community interest in pancreatic and glucose regulation research

Dose as reported

Class

Species

Route

Duration

Design

Source

500 mkg 2 times a day (morning and evening)

Human

human

Not reported

4 weeks

Trial in people without random groups · n = 12

Korkushko 2013

0,05 mg/animal per day

Animal

Macaca mulatta

intramuscularly

10 days

Study in live animals · n = 9

Goncharova 2015

50 μg/animal per day

Animal

rhesus monkey

intramuscularly

10 days

Study in live animals

Goncharova 2014

Context

Route

Amount

How often

How long

Agreement

Sources

Community interest in pancreatic and glucose regulation research

subcutaneous injection

1 to 2 mg per dose

once daily

10 to 20 days

Single non-vendor guide. The underlying community reports were not independently verified.

Pancragen (KEDW)

Pancragen (KEDW) at a glance

What is Pancragen?

Pancragen (KEDW) structure and chemistry